FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2905068088> ?p ?o ?g. }

• W2905068088 abstract "Prevention of mother-to-child transmission (MTCT) is an indispensable component in combatting the global AIDS epidemic. A combination of passive broadly neutralizing antibody (bnAb) infusion and active vaccination promises to provide protection of infants against MTCT from birth through the breastfeeding period and could prime the immune system for lifelong immunity. In this study, we investigate the impact of a single infusion of CD4 binding site (CD4bs) bnAb administered at birth on de novo antibody responses elicited by concurrent active HIV envelope vaccination. Four groups of infant macaques received active immunizations with subunit Env protein or modified vaccinia Ankara (MVA)-vectored Env and subunit Env protein, with or without a single intravenous coadministration of CH31 bnAb at birth. Vaccinated animals were monitored to evaluate binding and functional antibody responses elicited by the active vaccinations. Despite achieving plasma concentrations that were able to neutralize tier 2 viruses, coadministration of CH31 did not have a large impact on the kinetics, magnitude, specificity, or avidity of vaccine-elicited binding or functional antibody responses, including epitope specificity, the development of CD4bs antibodies, neutralization, binding to infected cells, or antibody-dependent cell-mediated cytotoxicity (ADCC). We conclude that infusion of CD4bs bnAb CH31 at birth does not interfere with de novo antibody responses to active vaccination and that a combination of passive bnAb infusion and active HIV-1 Env vaccination is a viable strategy for immediate and prolonged protection against MTCT.IMPORTANCE Our study is the first to evaluate the impact of passive infusion of a broadly neutralizing antibody in newborns on the de novo development of antibody responses following active vaccinations in infancy. We demonstrated the safety and the feasibility of bnAb administration to achieve biologically relevant levels of the antibody and showed that the passive infusion did not impair the de novo antibody production following HIV-1 Env vaccination. Our study paves the way for further investigations of the combination strategy using passive plus active immunization to provide protection of infants born to HIV-1-positive mothers over the entire period of risk for mother-to-child transmission." @default.
• W2905068088 created "2018-12-22" @default.
• W2905068088 creator A5002663565 @default.
• W2905068088 creator A5017115748 @default.
• W2905068088 creator A5019593843 @default.
• W2905068088 creator A5026874822 @default.
• W2905068088 creator A5035537196 @default.
• W2905068088 creator A5047594920 @default.
• W2905068088 creator A5050612131 @default.
• W2905068088 creator A5052768263 @default.
• W2905068088 creator A5056778092 @default.
• W2905068088 creator A5063142965 @default.
• W2905068088 creator A5063765589 @default.
• W2905068088 creator A5068160843 @default.
• W2905068088 creator A5068429270 @default.
• W2905068088 creator A5078111251 @default.
• W2905068088 creator A5084723811 @default.
• W2905068088 date "2019-03-01" @default.
• W2905068088 modified "2023-09-24" @default.
• W2905068088 title "Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques" @default.
• W2905068088 cites W1581959563 @default.
• W2905068088 cites W1656961899 @default.
• W2905068088 cites W1919421000 @default.
• W2905068088 cites W1965175217 @default.
• W2905068088 cites W1965986965 @default.
• W2905068088 cites W2002116074 @default.
• W2905068088 cites W2047426399 @default.
• W2905068088 cites W2057580133 @default.
• W2905068088 cites W2059777055 @default.
• W2905068088 cites W2063195211 @default.
• W2905068088 cites W2093961711 @default.
• W2905068088 cites W2098013141 @default.
• W2905068088 cites W2115951500 @default.
• W2905068088 cites W2116835799 @default.
• W2905068088 cites W2121096721 @default.
• W2905068088 cites W2142143280 @default.
• W2905068088 cites W2143421242 @default.
• W2905068088 cites W2152048324 @default.
• W2905068088 cites W2159515958 @default.
• W2905068088 cites W2162478418 @default.
• W2905068088 cites W2260877376 @default.
• W2905068088 cites W2321273585 @default.
• W2905068088 cites W2343862396 @default.
• W2905068088 cites W2347047438 @default.
• W2905068088 cites W2464058430 @default.
• W2905068088 cites W2565170802 @default.
• W2905068088 cites W2624564350 @default.
• W2905068088 cites W2745909422 @default.
• W2905068088 cites W2751251539 @default.
• W2905068088 cites W2754021327 @default.
• W2905068088 cites W2799371530 @default.
• W2905068088 cites W2886049060 @default.
• W2905068088 cites W4235232179 @default.
• W2905068088 doi "https://doi.org/10.1128/jvi.01783-18" @default.
• W2905068088 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6384077" @default.
• W2905068088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30541851" @default.
• W2905068088 hasPublicationYear "2019" @default.
• W2905068088 type Work @default.
• W2905068088 sameAs 2905068088 @default.
• W2905068088 citedByCount "17" @default.
• W2905068088 countsByYear W29050680882019 @default.
• W2905068088 countsByYear W29050680882020 @default.
• W2905068088 countsByYear W29050680882021 @default.
• W2905068088 countsByYear W29050680882022 @default.
• W2905068088 countsByYear W29050680882023 @default.
• W2905068088 crossrefType "journal-article" @default.
• W2905068088 hasAuthorship W2905068088A5002663565 @default.
• W2905068088 hasAuthorship W2905068088A5017115748 @default.
• W2905068088 hasAuthorship W2905068088A5019593843 @default.
• W2905068088 hasAuthorship W2905068088A5026874822 @default.
• W2905068088 hasAuthorship W2905068088A5035537196 @default.
• W2905068088 hasAuthorship W2905068088A5047594920 @default.
• W2905068088 hasAuthorship W2905068088A5050612131 @default.
• W2905068088 hasAuthorship W2905068088A5052768263 @default.
• W2905068088 hasAuthorship W2905068088A5056778092 @default.
• W2905068088 hasAuthorship W2905068088A5063142965 @default.
• W2905068088 hasAuthorship W2905068088A5063765589 @default.
• W2905068088 hasAuthorship W2905068088A5068160843 @default.
• W2905068088 hasAuthorship W2905068088A5068429270 @default.
• W2905068088 hasAuthorship W2905068088A5078111251 @default.
• W2905068088 hasAuthorship W2905068088A5084723811 @default.
• W2905068088 hasBestOaLocation W29050680881 @default.
• W2905068088 hasConcept C14086860 @default.
• W2905068088 hasConcept C159047783 @default.
• W2905068088 hasConcept C159654299 @default.
• W2905068088 hasConcept C179223381 @default.
• W2905068088 hasConcept C203014093 @default.
• W2905068088 hasConcept C22070199 @default.
• W2905068088 hasConcept C2778668663 @default.
• W2905068088 hasConcept C2779261636 @default.
• W2905068088 hasConcept C2779341262 @default.
• W2905068088 hasConcept C86803240 @default.
• W2905068088 hasConcept C8891405 @default.
• W2905068088 hasConceptScore W2905068088C14086860 @default.
• W2905068088 hasConceptScore W2905068088C159047783 @default.
• W2905068088 hasConceptScore W2905068088C159654299 @default.
• W2905068088 hasConceptScore W2905068088C179223381 @default.
• W2905068088 hasConceptScore W2905068088C203014093 @default.
• W2905068088 hasConceptScore W2905068088C22070199 @default.
• W2905068088 hasConceptScore W2905068088C2778668663 @default.

• next